Investors

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 14 September 2020 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 11 November 2020.

The Company further advises that it has not yet received the Funds.  The Company is in advanced discussions with ECP and believes that a further extension for the receipt of the Funds will be agreed to the mutual benefit of both companies in the very near future.  A further announcement will be made in due course

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiÞed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reßect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.